EUVIMEDEUVIMED entdecken
Crossref

Marketing Status and Brand‐Name Drug Prices: Evidence From Rx‐To‐OTC Switch

Lin Lin, Bo Wang iD

Health Economics · 2025

DOI: 10.1002/hec.4952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Economics, 2025. Verfasst von Lin Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Management, East China Normal University, Shanghai, China. Hauptthemen laut MEDLINE: Nonprescription Drugs, Prescription Drugs, Drug Costs, Marketing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study examines the impact of marketing status on brand‐name pricing by exploiting Prescription to over‐the‐counter (Rx‐to‐OTC) switches between 2001 and 2016. Using a Stacked difference‐in‐differences design, we find that the retail prices of brand‐name drugs reduce substantially following an Rx‐to‐OTC switch, while accounting for potential confounding factors related to patent expiration and generic entry. We show that the reduction in branded prices is primarily driven by increases in patient price elasticity in the OTC market. These results highlight the need to improve patient price sensitivity to address the rising prices of brand‐name prescription drugs in the United States, especially those with characteristics similar to over‐the‐counter drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nonprescription DrugsPrescription DrugsDrug CostsMarketingHumansUnited StatesDrugs, GenericCommerce

Stichwörter der Autor:innen

Rx‐to‐OTC switchbrand‐name drug pricemarketing statuspharmaceutical coststacked difference‐in‐differences

Substanzen

Nonprescription DrugsPrescription DrugsDrugs, Generic

Autor:innen und Institutionen

  • School of Public Management, East China Normal University, Shanghai, China.
  • School of Finance, Nankai Research Center for Health Economics and Medical Insurance, Nankai University, Tianjin, China.

ORCID-Profile: Bo Wang

Förderung

  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Lin, L., & Wang, B. (2025). Marketing Status and Brand‐Name Drug Prices: Evidence From Rx‐To‐OTC Switch. Health Economics. https://doi.org/10.1002/hec.4952

Vancouver

Lin L, Wang B. Marketing Status and Brand‐Name Drug Prices: Evidence From Rx‐To‐OTC Switch. Health Economics. 2025. doi:10.1002/hec.4952

BibTeX
@article{Lin2025,
  author = {Lin, Lin and Wang, Bo},
  title = {Marketing Status and Brand‐Name Drug Prices: Evidence From Rx‐To‐OTC Switch},
  journal = {Health Economics},
  year = {2025},
  doi = {10.1002/hec.4952}
}
Kostenlos starten →